Main Uses and Benefits of Moxiclear

Moxiclear is a broad-spectrum topical solution formulated for the treatment and prevention of various parasitic infections in companion animals. It contains a combination of active ingredients designed to address both external parasites, such as fleas and mites, and internal parasites, including certain types of intestinal worms and heartworm larvae.

Treatment and Prevention of Flea Infestations

Moxiclear is primarily used to treat and prevent flea infestations. It works by killing adult fleas on the animal and can also assist in the management of flea allergy dermatitis, a skin condition caused by a hypersensitivity to flea saliva. Regular application helps to break the flea life cycle, reducing the risk of re-infestation within the household environment.

Management of Mite Infestations

The medication is effective against several types of mites that cause skin irritation and discomfort. This includes:

• Ear Mites: Treatment of infestations in the ear canal.
• Sarcoptic Mange: Management of skin infestations caused by burrowing mites.
• Demodectic Mange: Treatment of overgrowths of mites that naturally reside in the hair follicles.

Prevention of Heartworm Disease

Moxiclear is used as a preventative measure against heartworm disease. When applied monthly, it targets the larval stages of the heartworm parasite that are transmitted through mosquito bites, preventing them from developing into adult worms that can cause significant damage to the heart and lungs.

Control of Intestinal Nematodes

The solution is effective in treating and controlling common gastrointestinal parasites, specifically roundworms and hookworms. These parasites can affect the overall health and nutritional status of the animal, and their management is a key component of routine parasite control.

Lungworm Prevention and Treatment

In certain species, Moxiclear is utilized to treat or prevent infections caused by lungworms. These parasites inhabit the respiratory system and can lead to coughing or more severe breathing difficulties if left unmanaged.

Regulatory References

1. HPRA Summary of Product Characteristics for Moxiclear

Moxiclear is a Veterinary Medicinal Product and its eligibility is defined strictly for specific animal populations (dogs, cats, and ferrets).

Populations for Whom Use is Contraindicated

Classification	Population/Condition
Age Restriction	Kittens under 9 weeks of age; Puppies under 7 weeks of age.
Hypersensitivity	Animals with known hypersensitivity to the active substances (imidacloprid, moxidectin) or any excipients.
Disease State	Dogs classified with Class 4 heartworm disease (safety has not been evaluated).
Species/Formulation	Canaries; Ferrets using the Large Cat (0.8 mL) or any Dog size presentations.

---

Populations Requiring Conditional or Restricted Use

Classification	Condition for Restricted Use
Physiological Status	Pregnant and Lactating animals; safety is not established, and use must be based on a veterinarian's benefit-risk assessment.
Health Status	Sick, debilitated, or underweight animals; use with caution based on a benefit-risk assessment.
Breed Sensitivity	Collies, Old English Sheepdogs, and related crossbreeds; oral uptake must be prevented due to potential moxidectin sensitivity.

For animals outside these parameters, or those with underlying conditions like severe Notoedres cati infestation (in cats) or microfilaremia (in dogs), the regulatory label stipulates that a veterinary assessment is required to manage the use of the product.

The regulatory documentation for Moxiclear establishes a highly specific interaction profile, defined by one mandatory class restriction and a documented absence of observed interactions with routine veterinary medical substances.

Interaction Profile Restrictions

Category	Official Regulatory Statement
Prohibited Combinations	Co-administration of any other antiparasitic macrocyclic lactone is explicitly restricted and should not occur during the course of Moxiclear treatment. This is the primary mandated constraint.
Pharmacodynamic & PK Interactions	The official regulatory label states that no interactions have been observed between this product and routinely used veterinary medicinal products. Consequently, no specific pharmacokinetic interactions (like CYP enzyme effects or changes to AUC/ C max) are documented.
Procedural Context	The absence of observed interactions also applies to standard medical or surgical procedures, allowing routine veterinary care to proceed without specific drug interaction concerns.
Timing & Dietary Rules	No mandatory timing separation rules are documented for co-administered routine medications. Additionally, no interactions with food, supplements, or herbal products are explicitly listed in the regulatory profile for this topical solution.

This structured profile is based on the Summary of Product Characteristics (SmPC) issued by government health agencies. The regulatory structure provides one mandatory restriction targeting a known related drug class. This is paired with a general statement that classifies the use of most other common veterinary therapeutics as non-interacting, based on the documented findings of the official assessment.

Dual-Action Neurotransmitter Receptor Modulation

This section outlines how the two active ingredients, Moxidectin and Imidacloprid, engage distinct neurotransmitter receptor systems to induce the complete disruption of physiological functions in target organisms. Moxidectin acts as an agonist on specific Glutamate-Gated Chloride Channels, while Imidacloprid acts as an agonist on nicotinic acetylcholine receptors in the invertebrate nervous system. This simultaneous, dual-receptor modulation is essential for the resulting physiological consequences on multiple classes of target organisms.

---

Paralysis via Ion Flux and Signal Blockade

The mechanism is defined by a two-pronged attack on nerve signaling integrity. One component initiates a sequence where massive chloride ion influx causes sustained hyperpolarization, leading to the flaccid paralysis of motor and feeding muscles. The second component causes initial nerve overstimulation followed by total functional blockade, resulting in spastic paralysis. These two mechanistic cascades combine to inhibit all motor function and regulatory processes in the target organisms.

Moxiclear is a spot-on solution intended for external use only on the skin of dogs or cats, as indicated by the specific product formulation. This treatment is generally administered at monthly intervals for the prevention of heartworm and for the control of most external and internal parasites, including fleas and various types of worms.

Dosage and Administration

To ensure correct dosing, your animal’s body weight must be accurately determined. The recommended minimum dose is 10 mg/kg bodyweight for the active substance imidacloprid and 2.5 mg/kg bodyweight moxidectin for dogs, or 1.0 mg/kg moxidectin for cats, delivered by the appropriate pipette size.

Animal Weight	Application Site (Dogs up to 25 kg and Cats)
All Weights	Part the hair and apply directly onto the skin in one spot
Dogs Over 25 kg	Evenly apply the entire content as 3 or 4 spots along the back from the shoulders to the base of the tail

1. Remove the pipette from the sachet and twist or snap back the tip.
2. Ensure the animal is standing and part the hair at the base of the skull (cats) or between the shoulder blades (small dogs) until the skin is visible. For large dogs, apply along the back in multiple spots.
3. Squeeze the pipette firmly to empty the entire contents directly onto the skin. Do not apply an excessive amount at any one spot.

Precautions

Avoid contact with the animal’s eyes or mouth. Do not allow the animal to lick the application sites until the product is dry. Ensure the application site is dry before allowing contact with fabrics or other materials, as the solvent may cause damage. Wash hands thoroughly after application. For heartworm prevention, treatment should start one month before the first expected exposure to mosquitoes.

Research evidence / Overview of studies for Moxiclear

The research on Moxiclear consists of studies, primarily controlled clinical trials and laboratory experiments, used to evaluate its use across several major parasitic conditions in animals. This evidence contributes to understanding the patterns observed during study evaluations.

---

Evidence for Heartworm Prevention and Microfilariae Treatment

Studies for the prevention of heartworm disease (caused by Dirofilaria immitis) are typically conducted as randomized, controlled trials and specialized prevention studies. These research projects examine the medicine’s use in preventing the development of heartworm larvae into the adult stage. The primary objective was to measure the non-development of adult heartworms in the target species when monitored on the study regimen.

Studies describe patterns where the non-development of adult heartworms was observed in the studied populations during the research interval. Research also explored the medicine's use in animals already carrying the infection, with findings describing measured changes in the levels of circulating microfilariae (the heartworm offspring) during defined study periods. However, there is no available research characterizing the medicine as an adulticidal treatment, meaning it is not studied for eliminating existing adult heartworms.

---

Evidence for Flea and Biting Lice Control

Clinical efficacy field trials and controlled laboratory studies have been studied for evaluating the medicine’s use in managing infestations of fleas (Ctenocephalides felis) and biting lice (Trichodectes canis). These studies focus on outcomes related to physical discomfort and outcomes linked to inflammatory or irritative states caused by these external parasites.

Studies report patterns where the quantification of adult flea population counts was measured and tracked over the defined observation intervals. Findings indicate that flea population counts were monitored over several weeks during the study period. Evidence for control is primarily focused on the adult parasite stage, and data regarding the long-term action against the pre-adult stages of fleas remain limited.

---

Evidence in Specific Populations and Research Gaps

Studies monitored the medicine’s use in age-gated populations, including puppies (dogs 7 weeks old) and kittens (cats 9 weeks old). Evidence is limited in several other important subgroups. Safety during pregnancy and lactation has not been established in the target species, with existing component-level data derived from laboratory animals. Clinical safety and research evaluation are also not established for dogs with the most severe classification of heartworm disease (Class 4).

Key Studies & References

1. SUMMARY OF PRODUCT CHARACTERISTICS (SPC) - Moxiclear 80 mg + 8 mg spot-on solution for large cats (Regulatory Document)
2. SUMMARY OF PRODUCT CHARACTERISTICS (SPC) - Moxiclear 100 mg + 25 mg spot-on solution for medium dogs (Regulatory Document)
3. Imidacloprid for Removal and Control of Fleas on Dogs (Review/Sarcoptic Mange Study Citation)

Common questions about Moxiclear (FAQ)

---

Q: What is the expected timeframe for Moxiclear to begin killing fleas after application?

Regulatory documents indicate a rapid onset of action. Study findings describe effects where flea feeding stopped within 3–5 minutes of contact. Official reports further suggest that the medicine can kill both adult fleas and flea larvae within 20 minutes of contact with the treated animal.

---

Q: How long after application does it take for Moxiclear to be water-resistant?

Official regulatory sources state that Moxiclear is considered to be water-resistant once the application site is fully dry. The product is stated to achieve water resistance approximately 2 hours after being applied.

---

Q: What are the ingredients in Moxiclear that make it toxic to aquatic life?

The precautionary statements on the official label are due to environmental safety concerns. Regulatory documentation specifically identifies the active ingredient moxidectin as the component that is highly toxic to aquatic organisms, such as fish and certain invertebrates.

---

Q: Are there different formulations of Moxiclear for dogs and cats, and if so, why?

Yes, official labels confirm that Moxiclear has different formulations for dogs and cats. The primary difference is the concentration of the active ingredient moxidectin. This difference is described as necessary to achieve the required therapeutic dose in each species.

---

Q: Does the application of shampoo reduce the effectiveness of Moxiclear after the drying period?

Regulatory information indicates that Moxiclear remains efficacious even after the animal has been shampooed following the application period. This statement is contingent on the use of a soap-free shampoo after the product is dry, as described in the label.

---

Q: What should be done if the animal's fur appears greasy or sticky at the application site for several days?

Greasy or sticky fur at the application site is a commonly observed and documented adverse reaction. Official safety information indicates this change is typically temporary and is generally observed to resolve without specific intervention.

---

Q: Does Moxiclear treat internal parasites like tapeworms, or is a separate product needed?

Official product labeling states that Moxiclear is not indicated for the control of tapeworms. Consequently, treatment for these particular internal parasites typically involves the use of a separate, specific agent.

---

Q: Why is the product described as having no strong chemical smell?

Regulatory safety data sheets describe the physical characteristics of the product, noting that it has no strong chemical smell. This is a purely factual description from the product's official assessment and is often described as having only a mild odour.

---

Q: Is it normal to see some fleas a few days after applying Moxiclear, or does it mean the product didn't work?

It is possible to see adult fleas days after treatment, as the product does not prevent pre-existing fleas from emerging from the surrounding environment. The product works by killing these new adults quickly, which is why a monthly application is required to manage the reinfestation cycle over time.

---

Q: What is the purpose of the 'inactive ingredients' or solvents in the Moxiclear formulation?

The inactive ingredients include a solvent that is utilized to facilitate the topical application of the active substances, moxidectin and imidacloprid. Regulatory precautions highlight that this component may temporarily stain or damage certain household materials until the application site is completely dry.

---

Q: Is Moxiclear effective against mites, such as those that cause sarcoptic mange or ear mites?

Moxiclear is formally indicated for the treatment and control of both sarcoptic mange and ear mites in the target animal species.

How to Store and Dispose of Moxiclear?

Moxiclear must be stored and handled according to the specific conditions defined in its official regulatory labeling to ensure stability and environmental safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store below 25°C. Do not freeze.
Protection	Store in the original package to protect it from light and moisture.
Child Safety	Keep out of sight and reach of children.
Stability	The sealed product has a labeled shelf life of two years.

Disposal Instructions

Official disposal procedures address both general waste and environmental protection:

• General Disposal: Unused product and waste materials must be disposed of in accordance with local requirements.
• Environmental Rule: The product must not enter water courses as it is harmful to aquatic organisms. Treated animals should not be allowed to swim in surface waters for four days following treatment.